Palladio Biosciences

Palladio Biosciences, Inc. is a biotechnology company focused on developing transformative medicines for orphan diseases of the kidney. Founded in 2015 and based in Horsham, Pennsylvania, the company is in the clinical stage and specializes in therapeutics aimed at renal diseases, particularly polycystic kidney disease (PKD). One of its key developments is Lixivaptan, a selective vasopressin V2 receptor antagonist designed to treat PKD, a life-threatening genetic disorder characterized by the growth of numerous fluid-filled cysts in the kidneys. Palladio Biosciences aims to provide innovative treatment options that can help prevent the progression of kidney diseases.

Lorenzo Pellegrini

Founder, COO and Board Member

Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.